Management of LDL as a Risk Factor. Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil

Similar documents
CVD risk assessment using risk scores in primary and secondary prevention

Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD

Alirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials

Lipid Lowering in Patients at High Risk for Cardiovascular Disease

The Target is LDL, HDL not so much

Review of guidelines for management of dyslipidemia in diabetic patients

What Role do the New PCSK9 Inhibitors Have in Lipid Lowering Treatment?

Novel PCSK9 Outcomes. in Perspective: Lessons from FOURIER & ODYSSEY LDL-C. ASCVD Risk. Suboptimal Statin Therapy

Metabolism, Atherogenic Properties and Agents to reduce Triglyceride-Rich Lipoproteins Manfredi Rizzo, MD, PhD

ATP IV: Predicting Guideline Updates

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer

Randomized Comparison of the Safety, Tolerability, and Efficacy of Long-term Administration of AMG 145: 52-Week Results From the OSLER Study

Effect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes

Cholesterol; what are the future lipid targets?

Aggressive Lipid Management for Diabetes

LDL cholesterol and cardiovascular outcomes?

Contemporary management of Dyslipidemia

Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient

Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman

AIM HIGH for SATURN and stay SHARP; COURAGE (v1.5)

Safety of Anacetrapib in Patients with or

Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital

Is Lower Better for LDL or is there a Sweet Spot

ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future

CETP inhibition: pros and cons. Philip Barter The Heart Research Institute Sydney, Australia

Weigh the benefit of statin treatment: LDL & Beyond

Familial Hypercholesterolemia New treatments

Disclosures. Objectives 2/11/2017

There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?

PCSK9 for LDL Cholesterol Reduction: What have we learned from clinical trials?

Joslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia

Beyond HDL: new therapeutic targets

Industry Relationships and Institutional Affiliations

Lipids: new drugs, new trials, new guidelines

PCSK9 Inhibitors and Modulators

Presenter Disclosure Information

Statins and PCSK9 inhibitors for stroke prevention

2016 ESC/EAS Guideline in Dyslipidemias: Impact on Treatment& Clinical Practice

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009

Approach to Dyslipidemia among diabetic patients

PCSK9 inhibition in homozygous familial hypercholesterolaemia

The TNT Trial Is It Time to Shift Our Goals in Clinical

Defining and Controlling Severe Familial Hypercholesterolemia

Effective Treatment Options With Add-on or Combination Therapy. Christie Ballantyne (USA)

CCC Dyslipidemia Lipid lowering/atherosclerosis clinical trials update. November 17 th, 2018

Decline in CV-Mortality

10/15/2012. Lessons Learned from Tim Russert: Investigating Residual Risk. Tim Russert: Residual CV Risk?

Prospective Natural-History Study of Coronary Atherosclerosis

New Approaches to Lower LDL-C

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

Efficacy and Safety of Alirocumab in Patients with Hypercholesterolemia not on Statin Therapy: the ODYSSEY CHOICE II Study

PCSK9 Inhibitors: A View of Clinical Studies

Beyond LDL-Cholesterol

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study

Copyright 2017 by Sea Courses Inc.

Defining Severe Familial Hypercholesterolemia. Raul D. Santos MD, PhD Brazil

2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD

Cholesterol, guidelines, targets and new medications

FOURIER: Enough Evidence to Justify Widespread Use? Did It fulfill Its Expectations?

Statins ARE Enough For The Prevention of CVD! Professor Kausik Ray Imperial College London, UK

Farmaci innovativi in ambito cardiovascolare: considerazioni di Farmacologia. Prof. Alberto Corsini University of Milan, Italy

MS Sabatine, RP Giugliano, AC Keech, PS Sever, SA Murphy and TR Pedersen, for the FOURIER Steering Committee & Investigators

Anne Carol Goldberg, MD, FACP, FAHA, FNLA Washington University, St. Louis, MO USA

Goal Achievement after Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects (GAUSS): Results from a

A Phase 3 Study of Lomitapide, a Microsomal Triglyceride Transfer Protein (MTP) Inhibitor, in Patients with Homozygous Familial Hypercholesterolemia

JAMA. 2011;305(24): Nora A. Kalagi, MSc

Non alcoholic fatty liver disease and atherosclerosis Raul Santos, MD

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Treatment of Atherosclerosis in 2007

New ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough?

Introduction. Objective. Critical Questions Addressed

The Clinical Unmet need in the patient with Diabetes and ACS

Tuesday, October 18 3:30 p.m. 5:30 p.m. Convention Center: Rooms 315 & 316

David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon

Fasting or non fasting?

Advances in Lipid Management

Drug Class Monograph

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

STATIN THERAPY IN THE ELDERLY: THERE ARE MILES TO GO BEFORE WE SLEEP

Inhibition of PCSK9: The Birth of a New Therapy

New Horizons in Dyslipidemia Management in Primary Care

Evolving Concepts on Lipid Management from Ezetimibe (IMPROVE IT) to PCSK9 Inhibitors

How to Reduce Residual Risk in Primary Prevention

Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both

Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies

Cardiovascular Complications of Diabetes

Considerations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction

2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.

Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL

CLINICAL OUTCOME Vs SURROGATE MARKER

Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN

Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects on Remnant-like Particle Cholesterol From the MARINE and ANCHOR Studies

Zuhier Awan, MD, PhD, FRCPC

Managing Dyslipidemia in Disclosures. Learning Objectives 03/05/2018. Speaker Disclosures

PCSK9 inhibition across a wide spectrum of patients: One size fits all?

STATIN UTILIZATION MANAGEMENT CRITERIA

What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?

Tuesday, October 18 3:30 p.m. 5:30 p.m. Convention Center: Rooms 315 & 316

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Metabolism and Atherogenic Properties of LDL

Transcription:

Management of LDL as a Risk Factor Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil

Disclosure Consulting for: Merck, Astra Zeneca, ISIS- Genzyme, Novo-Nordisk, BMS, Pfizer, Lilly, Amgem, Aegerion, Sanofi Sponsored research: ISIS-Genzyme, GSK, and Roche Speakers Bureau: Pfizer, Merck, Astra Zeneca, Abbott, Biolab and Novartis

Management of LDL as a Risk Factor Epidemiological association of cholesterol and CVD Evidence for cholesterol lowering Safety and cost effectiveness Statins and diabetes onset Unmet needs The future

LDL particles Source: The Lancet 2010; 375:959-961 (DOI:10.1016/S0140-6736(10)60364-9)

What is the importance of cholesterol for CVD?

Blood cholesterol and vascular mortality by age, sex and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths Lancet 2007; 370: 1829-39

N=900,000 Lancet 2007; 370: 1829 39

What is non-hdl cholesterol? Triglycerides Cholesterol All lipoproteins HDL LDL IDL VLDL CM remnants apoa-i apob apob apob apob 48 non-hdl Courtesy Roger Blumenthal non HDL-C = Total Cholesterol HDL-C

Non-HDL-cholesterol, CHD and, Ischemic Stroke N=302,430 4X more potent for CHD vs. Stroke N=173,312 CHD Ischemic Stroke FUP 2.79 million /persons years JAMA 2009;302:1993-2000

Intervention studies with statins What s the evidence?

Lancet 2010.; 376:1670-81

Impact of 40 mg/dl reduction on LDL-C upon major cardiovascular events and mortality CTT 2010 Relative Risk (95% CI) All cause mortality CHD mortality Other cardiac deaths Stroke deaths Major vascular events Non-fatal MI Myocardial revascularization Ischemic stroke Cancer incidence Hemorrhagic stroke 0.90 (0.87-0.93), p<0.0001** 0.80 (0.74 0.87); p<0.0001** 0.89 (0.81 0.98); p=0.002** 0.96 (0.84 1.09); p=0.5 0.78 (0 76 0 80); p<0.0001 0.73 (0.70 0.77); p<0.0001 0.75 (0.72 0.78); p<0.0001 0.79 (0.74 0.85); p<0.0001 1.00 (0.96 1.04); p=0.9 1.12 (0.93 1.35); p=0.2 Adapted from The Lancet 2010.; 376:1670-81 **- CI 99%

Reduction in CHD Events % Risk Reduction (%) in CHD Events p/ 39 mg/dl LDL-C Lowering According to Treatment Length 1 st year 2 nd year 3 rd to 5 th years >6 th year -11-22 -33-36 Adapted from Law MR et al BMJ 2003;326:1423

+ Importance of reducing non-hdl-c 1% non-hdl-c = 1% CHD risk Evaluated studies 14 with statins (n=100,827) 7 with fibrates (n=21.647) 6 with niacin (n=4.445) 1 with resins (n=3.806) 1 with diet (n=458) 1 with ileal bypass (n=838) TOTAL 132,021 patient AVERAGE FOLLOW-UP 4.5 Y J Am Coll Cardiol 2009;53:316-322

The ideal cholesterol level? Is really lower the better?

LDL-C of MI Subjects in The USA: Primary Prevention 2000-2006 LDL N=48,093 >130 mg/dl 27.9% 100-129 mg/dl 30.6% < 100 mg/dl 41.5% <70 mg/dl = 12.5% Sachedeva A et al. Am Heart J 2009;157:111-7

Relative risk of CHD death Low Cholesterol A China Business? 2.0 MRFIT 1.0 0.5 0.5 0.25 0.125 Shanghai Chen et al. BMJ. 1991;303:276-82. Kannel et al. Am Heart J. 1986 112:825-36. 116 156 194 233 Total Plasma Cholesterol (mg/dl) 272

Proportional reduction in atherosclerotic event rate (95% CI) CTT: Effects on Major Atherosclerotic Events 30% Statin vs control (21 trials) 25% 20% 15% More vs Less (5 trials) 10% 5% 0% 0 10 20 30 40 Mean LDL cholesterol difference between treatment groups (mg/dl) Lancet 2010.; 376:1670-81

What is the cost effectiveness of LDL-C lowering? Who will benefit the most?

Baseline LDL-C and risk reduction Lancet 2010.; 376:1670-81

Cardiovascular events per 40 mg/dl reduction in LDL-C in 5 years: CTT Mean LDL-C 148 (118-190) mg/dl Relative risk reduction Primary Prevention 20% 20% Secondary Prevention Absolute risk reduction Events avoided per 1,000 (CI 95%) 2% 5% 25 (19-31) 48 (39-57) NNT 50 20 Adapted from CTT Lancet 2005;366:1267-78

Does cholesterol lowering cause cancer?

Alsheikh-Ali et al. JACC 2008;52:1141-7

LDL-C Reduction and Cancer Incidence Lancet 2010.; 376:1670-81

Do Statins Increase the Risk of Type 2 Diabetes?

Statins and The Risk of Diabetes: Meta-analysis Relative increment 9% NNH= 255 Source: The Lancet 2010; 375:735-742 (DOI:10.1016/S0140-6736(09)61965-6)

Meta-analysis of New-Onset Diabetes and First Major Cardiovascular Events in 5 Large Trials Comparing Intensive-Dose to Moderate-Dose Statin Therapy Preiss, D. et al. JAMA 2011;305:2556-2564 NNH=498/ year NNT= 155/year

Risk of new-onset T2DM: baseline fasting glucose > 100 mg/dl, fasting triglycerides>150 mg/dl, BMI >30 kg/m2, and a history of hypertension Waters DD et al. JACC 2011; 57:1535-45

Do Statins Increase The Risk of Hemorhagic Stroke?

N=248,391 Randomized Trials Observational Studies Hackman et al. Circulation 2011 17 Nov e-pub

Do Statins Cause Cognitive Changes?

FDA: Statins can cause cognitive changes that are generally reversible 333 cases in post-marketing surveys HPS- memory loss objectively measured by TICS questionnaire 23.4% vs. 24.2 % simvastatin vs. placebo p=0.4 Dementia 0.3% vs. 0.3% Other phsyquiatric changes 0.7% vs. 0.7% Lancet 2002;360: 7 22

Statins and severe muscle damage

Severe muscle disease with statins: CTT N=170,000 in 26 trials Defined ad CK levels > 10 x ULN Simvastatin 80 mg vs. 20-40 mg 4/10,000 vs 1/10,000 Not seen with high dose atorvastatin Not associated with LDL-C lowering Lancet 2010.; 376:1670-81

What are the unmet needs?

% Rates of CHD Patients Attaining LDL-C <70 mg/dl according to gender:ltap-2 n=2993 Gender Total 879/2993 Women 242/940 242/940 242/940 Success Faillure Men 637/2053 637/2053 P=0.0033 Santos RD et al. Am Heart J 2009;158:860-6

% Non-HDL-C Success Rate by Risk Group Risk Groups 6224/9955 1784/2066 1370/1959 3070/5930 P<0.001 among risk groups. Risk group and success determined according to NCEP ATP III guidelines. Santos RD et al. Atherosclerosis 2012; 224:150-3

What is the future? Present in some cases

Antisense oligonucleotides: mechanism of action DNA Transcription mrna Translation Traditional drug Disease-associated protein produced Transcription No translation Antisense drug (oligonucleotide) No disease-associated protein produced Adapted from: Crooke ST, ed. Antisense drug technology: principles, strategies and applications. 2nd ed. Boca Raton, FL: CRC Press, 2007:601

Raal FJ, Santos RD et al. Lancet. 2010;375:998-1006

Lomitapide: Mode of Action Diet Source triglyceride cholesterol Intestinal Cell MT P Chylomicron n Liver Source triglyceride cholesterol Apo B-48 Liver Cell MTP Decreases Secretion into Bloodstream Apo B-100 VLDL 41

Mean % Change in LDL-C from BL (95% CI) Lomitapide Efficacy in Phase 3 (Completer Population, N=23) Efficacy Phase Safety Phase 50% Reduction 44% Reduction p<0.001 p<0.001 Mean Dose: 45 mg Mean Dose: 40 mg Study Week LDL-C 352 ± 116 168 ± 96 (mg/dl): Baseline Week 26 Adapted from Cuchel M et al. Lancet 2013; 381:40-46 199 ± 123 Week 56

Impact of an PCSK9 mab on LDL Receptor Expression For illustration purposes only

LAPLACE-TIMI 57: Mean Change in LDL-C from Baseline While Receiving Statin Therapy to Week 12 With AMG 145 Intervention Baseline LDL-C (mg/dl) % Change LDL-C Attained LDL-C (mg/dl) Placebo 124 AMG 145 70 mg Q2W 120-42%* 73 AMG 145 105 mg Q2W 128-60%* 54 AMG 145 140 mg Q2W 120-66%* 45 AMG 280 280 mg Q4W 124-42%* 69 AMG 145 350 mg Q4W 124-50%* 60 AMG 145 420 mg Q4W 120-50%* 58 n = 631 * p < 0.0001 for % change in LDL-C vs placebo Giugliano et al. Lancet 2012; 380: 2007-17

% Change from Baseline to Week 12 Changes in Apo B, nonhdl-c, and Lp(a) from Baseline to Week 12 with Alirocumab 10 Apo B nonhdl-c Lp(a) 0-10 -20-2% -2% -0% -13% -30-40 -27%* -34%* -26%* -29%* -50-60 -70 1 LS mean (SE) 2 median (Q1-Q3) * p < 00001 p = 0.0022-48%* -56%* -56%* -63%* McKenney et al. J Am Coll Cardiol 2012;59 2344-2353

Conclusions 1 There is a clear association between cholesterol levels and the risk of CHD death Cholesterol lowering reduces the risk of cardiovascular events and mortality The absolute benefit depends on the risk Cholesterol reduction does not increase the risk of cancer, hemorrhagic stroke or cognitive dysfunction

Conclusions 2 Statin use is associated with an increase in the risk of type 2 diabetes Absolute risk is small Greater in those at higher risk of becoming diabetics at baseline There is plenty of room for improvement in prevention of subjects at high risk of CVD